Sodium‐glucose co‐transporter 2 inhibitors reduce the intravitreal anti‐ <scp>VEGF</scp> treatment necessity in eyes with early diabetic macular oedema: A post‐hoc analysis focusing on the fellow eye of the <scp>COMET</scp> trial
Systemic SGLT2i therapy reduced the need for intravitreal anti-VEGF treatment in eyes with early and mild DMO. These results suggest that SGLT2i may be effective in preventing the progression of early and mild DMO.
Authors
- Noriko Asaumi
- Toshiyuki Oshitari (ORCID: https://orcid.org/0000-0002-8273-845X)
- Tomoaki Tatsumi (ORCID: https://orcid.org/0000-0001-8271-9403)
- Takayuki Baba (ORCID: https://orcid.org/0000-0002-8178-8391)
- Masaya Koshizaka (ORCID: https://orcid.org/0000-0001-7374-9993)
- Yoko Takatsuna (ORCID: https://orcid.org/0000-0002-1209-0934)
- Tomomi Kaiho
- Yuki Shiko (ORCID: https://orcid.org/0000-0002-3959-9343)
- Koutaro Yokote (ORCID: https://orcid.org/0000-0003-3033-4813)
- Ryoichi Ishibashi (ORCID: https://orcid.org/0000-0003-2535-5396)
- Shuichi Yamamoto
Institutions
- Chiba University (JP)
- Kisarazu Hospital (JP)
- Chiba Rosai Hospital (JP)
- International University of Health and Welfare (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1111/dom.16636
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Taisho Toyama Pharmaceutical Company